Home-based neuro-cardiac rehabilitation in congenital heart disease: the QUALINEURO-REHAB trial study protocol.

BMJ OpenOct 5, 2026 (epub)
Clinical ResearchCardiologyPediatrics

Johanna Calderon, Sylvie Martins, Alfred Hager et al.

✦ AI-curated · Sources linked

In 30 seconds

The QUALINEURO-REHAB trial is a multicenter, two-arm randomized controlled trial assessing a home-based neuro-cardiac rehabilitation program in youth aged 8-25 with complex congenital heart disease (CHD). The study aims to compare the program's efficacy against standard care, focusing on health-related quality of life as the primary outcome, measured by the Pediatric Quality of Life Inventory score.

Key findings

  • Primary outcome measures health-related quality of life using the Pediatric Quality of Life Inventory.
  • Participants will be assessed at baseline and after 12 months.
  • The intervention includes 12 weeks of home-based cardiovascular rehabilitation and executive function training.

Why it matters

This study addresses the significant long-term morbidities associated with congenital heart disease, potentially improving both physical and mental health outcomes in affected youth through a structured rehabilitation program.

Source

PubMed · PMID 42833711

Published in BMJ Open. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.